MSD France
Division of Merck & Co. Inc.
www.msd-france.com
Latest From MSD France
AstraZeneca/MSD’s Koselugo Among 14 New Hopefuls At EMA
New drugs from Eli Lilly, Pfizer, Janssen, GSK, Arvelle, BioCryst, Diurnal and Myovant are also among the latest products the European Medicines Agency is evaluating for potential pan-EU approval.
Keytruda Dropped From England’s Cancer Drugs Fund For Bladder Cancer
MSD said it was disappointed by the decision by the health technology assessment body, NICE, and that it was considering what further actions are available to ensure eligible patients with advanced bladder cancer continue to have access to its medicine.
England’s NICE Rejects Tecentriq In Triple-Negative Breast Cancer
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.
New Keytruda Combo Wins Funding In England For NSCLC
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Michel Vounatsos, Managing Dir.
- Contact Info
-
MSD France
Phone: (33)
Paris,
France